|
|
|
Real Estate News Releases
|
(EMAILWIRE.COM, April 07, 2012 ) Lake Oswego, OR - Monster OTC (www.monsterotc.com) has found a report by Forbes that states that pharma giant Roche is interested in the potential blockbuster breast cancer drug NeuVax, which is being made by Galena Biopharma, Inc. (NasdaqCM: Gale).
This news shows that other big drug companies have a belief that NeuVax could go to market.
If NeuVax is approved, this drug could send shares of GALE flying.
More importantly is the lives it could save, because as Americans we need money to survive, so we want to see (GALE) hit $50, but as human beings, I think we speak for everyone when we say that we are more concerned with the lives NeuVax could save.
Here is the article from Forbes: http://goo.gl/kkwko
We at MonsterOTC.com hopes that CNBC, ABC, CBS, AOL, YAHOO, GOOGLE and others pick up this article, because the public needs to be aware of Galena Biopharma Inc. (GALE) and their drug NeuVax, which if approved could treat patients and potentially save many lives.
Other pharmaceutical and biotech companies garnering investors attention include, Keryx Biopharmaceuticals Inc. (NasdaqCM: KERX), that took a beating last week when one of their drug candidates was dismissed.
Keryx Biopharmaceuticals Inc. (KERX) still has a good looking pipeline and hopefully their other candidates do better.
Human Genome Sciences Inc. (NasdaqGS: HGSI) is another stock that has taken a hit, as shares of HGSI are trading at $7.96.
(HGSI) has a 52 week high of $30.15.
Dendreon Corp. (NasdaqGS: DNDN) is yet another drug company that has took a hit, as shares are trading at $10.43, down 75% from their 52 week high of $43.96.
Monsterotc.com may have OTC in our name, but we have a knack for picking undervalued big boards that trade on the NYSE and Nasdaq, in fact we have a new pick coming up soon, so pease visit us at www.monsterotc.com today and be sure to sign up for our free email alerts.
About Monster OTC
Monster OTC is an investor relations site that provides free e-newsletters and stock alerts from its web site, http://www.monsterotc.com. The company covers all sectors of the market from undervalued penny stocks to big-board bottom bouncers.
Disclaimer: Monster OTC is not a registered investment advisor. Investors are responsible for doing their own research and obtaining professional investment advice. Monster OTC does not guarantee the accurateness of information in its communications. Investors should read the full disclaimer at http://www.monsterotc.com before investing in any stock featured by the site.
MonsterOTC.com
Alan Goldstein
855-840-2644
alerts@thestockfather.com 
|
|
|
|
Real Estate News by Sector
|
|
|
|
|
